
Study Sites Added to COMPOSE Clinical Trial of PRRT with 177Lu-Edotreotide
Additional US study sites are now participating in an ongoing clinical trial of peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide as a first or second
Additional US study sites are now participating in an ongoing clinical trial of peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide as a first or second
After being virtual since 2020, the North American Neuroendocrine Tumor Society (NANETS) met in person for its annual meeting in Washington DC in late October. NETRF CEO Elyse Gellerman and Director of Patient Education Jessica Thomas attended the NANETS Symposium to talk with NET specialists, a number of NETRF research grantees, and other NET patient advocacy groups. They joined more than 400 attendees dedicated to better understanding neuroendocrine cancer, improving patient care, and supporting patients through advocacy and education.
Brittany Holzhauer had her whole future planned. A self-professed “dreamer” with incredible determination, she started her career as pharmacist in 2018 and with her husband Luke, welcomed her first child, Lorelei, in June of 2019.
“In 2012, my husband was diagnosed with a neuroendocrine tumor (NET) cancer. At that time, there was little information and few treatment options,” said Suzanne Ludlow, NETRF Board Member and generous benefactor of NETRF’s second edition of “Neuroendocrine Cancer: A Guide for Patients and Families.” Suzanne lost her beloved husband Vincent in 2017, but she’s honoring his life while supporting other patients and families navigating NETs as a new member of the NETRF Board of Trustees. Read more about Suzanne and Vincent’s story here.
A new clinical trial being conducted at a single center in Switzerland aims to explore a therapy using a novel somatostatin receptor subtype 2 antagonist labelled with Terbium-161 (161Tb-DOTA-LM3). The study is sponsored by University Hospital, Basel, in collaboration with the Swiss National Science Foundation and the Paul Sherrer Institute and builds upon research funded by NETRF.
A patient advocacy-led clinical research study aims to determine if patients who have rare tumors can benefit from matched molecular therapy based on the results of their genomic profiling. Patients with neuroendocrine tumors and unknown primaries may be eligible for this study. Sponsored by the TargetCancer Foundation, in collaboration with Foundation Medicine Inc., the TCF-001 TRACK (Target Rare Cancer Knowledge) Study uses next-generation sequencing to develop a comprehensive genomic profile of each participant’s tumor as well as their plasma circulating cell-free DNA (blood).
Warwick, NY middle school Ukulele club raises $6,000 for NETRF
“Anything that I have done, and any impact I have made in support of NETRF is because of the lessons he taught me.” Erica Roberts, NETRF Champion Society Member
After Leanne lost her husband of 31 years to pancreatic neuroendocrine cancer (pNETs), she sold his most beloved possession, a Bass boat, and donated half of the proceeds to NETRF. Leanne, her son Justin and their family and friends have raised more than $35,000 in Michael’s name for NETRF. She shares their story.
A new phase II clinical trial is exploring the effects of two approved chemotherapy drugs administered after surgery to treat adult patients who have high-risk, well-differentiated pancreatic neuroendocrine tumors (pNETS).